CAN < CHE < CHL

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 49.
[0-20] [0 - 20][0 - 49][20-40]

Ident.	Authors (with country if any)	Title
000008 (1999)	J. H. Kordower ; J. Bloch ; S. Y. Ma ; YAPING CHU ; S. Palfi ; B. Z. Roitberg ; M. Emborg ; P. Hantraye ; N. Deglon ; P. Aebischer	Lentiviral gene transfer to the nonhuman primate brain
000154 (2000)	Jeffrey H. Kordower ; Marina E. Emborg ; Jocelyne Bloch ; Shuang Y. Ma ; YAPING CHU ; Liza Leventhal ; Jodi Mcbride ; Er-Yun Chen ; Stéphane Palfi ; Ben Zion Roitberg ; W. Douglas Brown ; James E. Holden ; Robert Pyzalski ; Michael D. Taylor ; Paul Carvey ; ZAODUNG LING ; Didier Trono ; Philippe Hantraye ; Nicole Deglon ; Patrick Aebischer	Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
000185 (2001)	F. Durif ; I. Devaux ; J.-J. Pere ; J.-C. Delumeau ; I. Bourdeix	Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's Disease and end-of-dose deterioration in daily medical practice : An open, multicenter study
000206 (2001)	S. Descombes ; A. M. Bonnet ; U. E. Gasser ; C. Thalamas ; J. Dingemanse ; I. Arnulf ; M. P. Bareille ; Y. Agid ; O. Rascol	Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease
000278 (2001)	Asteria Luzardo-Alvarez ; M. Begona Delgado-Charro ; José Blanco-Mendez	Iontophoretic delivery of ropinirole hydrochloride: Effect of current density and vehicle formulation
000445 (2003)	C. Crevoisier ; A. Monreal ; B. Metzger ; T. Nilsen	Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers
000472 (2003)	G. Fenelon ; S. Gimenez-Roldan ; J. L. Montastruc ; F. Bermejo ; F. Durif ; I. Bourdeix ; J.-J. Pere ; L. Galiano ; J. Schadrack	Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study
000501 (2003)	Charles Crevoisier ; Patricia Zerr ; Francoise Calvi-Gries ; Turid Nilsen	Effects of food on the pharmacokinetics of levodopa in a dual-release formulation
000586 (2003)	M. Desmurget ; S. T. Grafton ; P. Vindras ; H. Grea ; R. S. Turner	Basal ganglia network mediates the control of movement amplitude
000664 (2004)	M. Desmurget ; V. Gaveau ; P. Vindras ; R. S. Turner ; E. Broussolle ; S. Thobois	On-line motor control in patients with Parkinson's disease
000665 (2004)	Vincent Camus ; Hélène Kraehenbühl ; Martin Preisig ; Christophe J. Büla ; Gérard Waeber	Geriatric depression and vascular diseases: what are the links?
000690 (2004)	Stéphane Thobois ; Francois Vingerhoets ; Valerie Fraix ; Jing Xie-Brustolin ; Hélène Mollion ; Nicolas Costes ; Patrick Mertens ; Alim-Louis Benabid ; Pierre Pollak ; Emmanuel Broussolle	Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease. A positron emission tomographic study
000695 (2004)	Murat Emre ; Dag Aarsland ; Albeao Albanese ; E. Jane Byrne ; Günther Deuschl ; Peter P. De Deyn ; Franck Durif ; Jaime Kulisevsky ; Teus Van Laar ; Andrew Lees ; Werner Poewe ; Alain Robillard ; Mario M. Rosa ; Erik Wolters ; Peter Quarg ; Sibel Tekin ; Roger Lane	Rivastigmine for dementia associated with Parkinson's disease
000752 (2005)	Urs P. Mosimann ; René M. Müri ; David J. Burn ; Jacques Felblinger ; John T. O'Brien ; Ian G. Mckeith	Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies
000781 (2005)	Christian M. Müller ; Rob A. I. De Vos ; Claude-Alain Maurage ; Dietmar R. Thai ; Markus Tolnay ; Heiko Braak	Staging of sporadic parkinson disease-related α-synuclein pathology : Inter- and intra-rater reliability
000A53 (2007)	Mehdi Tafti ; Norbert B. Ghyselinck	Functional Implication of the Vitamin A Signaling Pathway in the Brain
000B27 (2008)	C. Cavin ; M. Marin-Kuan ; S. Langouët ; C. Bezencon ; G. Guignard ; C. Verguet ; D. Piguet ; D. Holzh User ; R. Cornaz ; B. Schilter	Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver
000B29 (2008)	Virginie Czernecki ; Michael Schüpbach ; Sadek Yaici ; Richard Levy ; Eric Bardinet ; Jérome Yelnik ; Bruno Dubois ; Yves Agid	Apathy Following Subthalamic Stimulation in Parkinson Disease : A Dopamine Responsive Symptom
000C25 (2009)	Elena Moro ; Niels Allert ; Roberto Eleopra ; Jean-Luc Houeto ; Tra-Mi Phan ; Herman Stoevelaar	A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease
000C36 (2009)	Samareh Azeredo Da Silveira ; Bernard L. Schneider ; Carmen Cifuentes-Diaz ; Daniel Sage ; Toufik Abbas-Terki ; Takeshi Iwatsubo ; Michaël Unser ; Patrick Aebischer	Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson's disease
000C49 (2009)	Paolo Viviani ; Pierre R. Burkhard ; Sabina Catalano Chiuve ; Corrado Corradi Dell'Acqua ; Philippe Vindras	Velocity control in Parkinson's disease : a quantitative analysis of isochrony in scribbling movements

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Merge

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA14s3.i -k "CHE" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA14s3.i  \
                -Sk "CHE" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Merge/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Merge
   |type=    indexItem
   |index=    FA14s3.i
   |clé=    CHE
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024